Gilead Sciences has announced that it will be webcasting its corporate presentation at three upcoming investor conferences in the US.
Along with the Rodman and Renshaw 10th Annual Healthcare Conference in New York, the company will also be present at Deutsche Bank 2008 DB-Biotech Boston Confab in Boston and the 17th Annual Credit Suisse Healthcare Conference in Phoenix.
An overview of the company will be presented by Kevin Young, Gilead's executive vice-president of commercial operations at the Rodman and Renshaw conference on November 10th and the Deutsche Bank Confab on November 11th.
The third seminar, the Credit Suisse Healthcare Conference, will have John Milligan, the company's president and chief operating officer, providing an overview on November 12th.
Earlier this month, the company announced two-year data from pivotal phase III studies, which evaluated the effect of Viread from chronic hepatitis B virus (HBV) sufferers.
Results of the tests found that patients who received the drug for up to 96 weeks experienced sustained suppression of HBV levels in the blood.
Based in Foster City, California, Gilead Sciences is a biopharmaceutical company that researches, develops and commercialises therapeutics, specialising in the care of patients suffering from life-threatening diseases worldwide.
The organisation has operations in Europe, Australia and North America.See all the latest jobs in Pharmaceutical